H.C. Wainwright analyst Yi Chen raised the firm’s price target on Regenxbio to $38 from $36 and keeps a Buy rating on the shares following the Q1 report. The firm says the company’s Duchenne muscular dystrophy pivotal trial of RGX-202 is slated to start in the second half of 2024.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX: